[1] Kikly K,Liu L,Na S,et al.The IL-23/Th17 axis:therapeutic targets for autoimmune inflammation.Curr Opin Immunol,2006,18(6):670-675.
[2] Wang H,Peters T,Kess D,et al.Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation.J Clin Invest,2006,116 (8):2105-2114.
[3] Luo X,Liu L,Tang N,et al.Inhibition of monncyte-derived dendritic cell differentiation and interleukin-12 production by complement iC3b via a mitogen-activated protein kinase signalling pathway.Exp Dermatol,2005,14(4):303-310.
[4] Toichi E,Torres G,McCormick TS,et al.An anti-IL-12p40 antibody down-regulates type 1 cytokines,chemokines,and IL-12/IL-23 in psoriasis.J Immunol,2006,177(7):4917-4926.
[5] Bergstrom L,Yocum DE,Ampel NM,et al.Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.Arthritis Rheum,2004,50(6):1959-1966.
[6] Reich K,Nestle FO,Papp K,et al.EXPRESS study investigators.Infliximab induction and maintenance therapy for moderate-tosevere psoriasis:a phase Ⅲ,multicentre,double-blind trial.Lancet,2005,366(9494):1367-1374.
[7] Bongartz T,Sutton AJ,Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA,2006,295(19):2275-2285.
[8] Hudson TJ.Skin barrier function and allergic risk.Nat Genet,2006,38(4):399-400.
[9] Menter A,Cather JC,Baker D,et al.The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.J Am Acad Dermatol,2006,54(1):61-63.
[10] Giardina E,Sinibaldi C,Chini L,et al.Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis(ATOD2) on human chromosome lq21.Hum Hered,2006,61(4):229-236.
[11] Proksch E,Folster-Holst R,Jensen JM.Skin barrier function,epidermal proliferation and differentiation in eczema.J Dermatol Sci,2006,43(3):159-169.
[12] Sugiura K,Muro Y,Nishizawa Y,et al.LEDGF/DFS70,a major autoantigen of atopic dermatitis,is a component of keratohyalin granules.J Invest Dermatol,2007,127(1):75-80.
[13] Cole GW,Silverberg NL.The adherence of Staphylococcus aureus to human corneocytes.Arch Dermatol,1986,122(2):166-169.
[14] Remitz A,Kyllonen H,Granlund H,et al.Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions.J Allergy Clin Immunol,2001,107(1):196-197.
[15] Inagaki N,Shiraishi N,Igeta K,et al.Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus,but not by dexamethasone.Eur J Pharmacol,2006,546 (1-3):189-196.
[16] Hanifin JM,Ling MR,Langley R,et al.Tacrolimus ointment for the treatment of atopic dermatitis in adult patients:part Ⅰ,efficacy.J Am Acad Dermatol,2001,44(1Suppl):S28-38.
[17] Koo JY,Fleischer AB Jr,Abramovits W,et al.Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis:results in 8000 patients.J Am Acad Dermatol,2005,53 (2 Suppl 2):S195-S205.
[18] Naylor M,Elmets C,Jaracz E,et al.Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.J Dermatolog Treat,2005,16(3):149-153.
[19] Jaracz E,Maher R,Simon D,et al.Safety profile of Tacrolimus ointment:data from five years of post-marketing experience.In:Proceedings of the 64th Annual Meeting of the American Academy of Dermatology,San Francisco,CA,2005.
[20] SEER.Surveillence,Epidemiology,End results[DB/OL] .http://seer.cancer.gov/csr/1975_2004/
[21] Frieling UM,Schaumberg DA,Kupper TS,et al.A randomized,12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study.Arch Dermatol,2000,136(2):179-184. |
